Tekmira Cuts Deal With Pfizer
Tekmira Pharmaceuticals, the Vancouver, BC-based developer of RNA interference drugs, said today it has formed a partnership with New York-based Pfizer (NYSE: PFE) to use its lipid-nanoparticle technology as a delivery vehicle for Pfizer’s RNAi drug candidates. Tekmira will make the drug formulations, while Pfizer will run the animal tests. This marks the latest significant partnership for Tekmira to use its RNAi technology, counting deals with Cambridge, MA-based Alnylam Pharmaceuticals and Roche. Terms of the Pfizer partnership weren’t disclosed.